125 results on '"Evans, Andrew H."'
Search Results
2. Parkinson's disease in the Western Pacific Region
- Author
-
Lim, Shen-Yang, Tan, Ai Huey, Ahmad-Annuar, Azlina, Klein, Christine, Tan, Louis C S, Rosales, Raymond L, Bhidayasiri, Roongroj, Wu, Yih-Ru, Shang, Hui-Fang, Evans, Andrew H, Pal, Pramod K, Hattori, Nobutaka, Tan, Chong Tin, Jeon, Beomseok, Tan, Eng-King, and Lang, Anthony E
- Published
- 2019
- Full Text
- View/download PDF
3. Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation
- Author
-
Sung, Simon, Vijiaratnam, Nirosen, Chan, Daniela Wan Chi, Farrell, Michael, and Evans, Andrew H.
- Published
- 2018
- Full Text
- View/download PDF
4. Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis
- Author
-
Sung, Simon, Vijiaratnam, Nirosen, Chan, Daniela Wan Chi, Farrell, Michael, and Evans, Andrew H.
- Published
- 2018
- Full Text
- View/download PDF
5. Cerebrospinal fluid neurofilament light and cerebral atrophy in younger‐onset dementia and primary psychiatric disorders.
- Author
-
Walia, Nirbaanjot, Eratne, Dhamidhu, Loi, Samantha M., Farrand, Sarah, Li, Qiao‐Xin, Malpas, Charles B., Varghese, Shiji, Walterfang, Mark, Evans, Andrew H., Parker, Shaun, Collins, Steven J., Masters, Colin L., and Velakoulis, Dennis
- Subjects
DEMENTIA ,CEREBROSPINAL fluid ,CYTOPLASM ,MENTAL illness - Abstract
Background and Aims: Neurodegeneration underpins the pathological processes of younger‐onset dementia (YOD) and has been implicated in primary psychiatric disorders (PSYs). Cerebrospinal fluid (CSF) neurofilament light (NfL) has been used to investigate neurodegeneration severity through correlation with structural brain changes in various conditions, but has seldom been evaluated in YOD and PSYs. Methods: This retrospective study included patients with YOD or PSYs with magnetic resonance imaging (MRI) of the brain and CSF NfL analysis. Findings from brain MRI were analysed using automated volumetry (volBrain) to measure white matter (WM), grey matter (GM) and whole brain (WB) volumes expressed as percentages of total intracranial volume. Correlations between NfL and brain volume measurements were computed whilst adjusting for age. Results: Seventy patients (47 with YOD and 23 with PSY) were identified. YOD types included Alzheimer disease and behavioural variant frontotemporal dementia. PSY included schizophrenia and major depressive disorder. MRI brain sequences were either fast spoiler gradient‐echo (FSPGR) or magnetization‐prepared rapid acquisition gradient‐echo (MPRAGE). In the total cohort, higher NfL was associated with reduced WB in the FSPGR and MPRAGE sequences (r = −0.402 [95% confidence interval (CI), −0.593 to −0.147], P = 0.008 and r = −0.625 [95% CI, −0.828 to −0.395], P < 0.001, respectively). Higher NfL was related to reduced GM in FSPGR (r = 0.385 [95% CI, −0.649 to −0.014], P = 0.017) and reduced WM in MPRAGE (r = −0.650 [95% CI, −0.777 to −0.307], P < 0.001). Similar relationships were seen in YOD, but not in PSY. Conclusion: Higher CSF NfL is related to brain atrophy in YOD, further supporting its use as a nonspecific marker of neurodegeneration severity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Practical approaches to commencing device‐assisted therapies for Parkinson disease in Australia
- Author
-
Williams, David R., Evans, Andrew H., Fung, Victor S. C., Hayes, Michael, Iansek, Robert, Kimber, Thomas, OʼSullivan, John D., and Sue, Carolyn M.
- Published
- 2017
- Full Text
- View/download PDF
7. Tremor Differentiating between causes.
- Author
-
YEUNG, ALEX and EVANS, ANDREW H.
- Abstract
The article focuses on the clinical assessment of tremor for diagnosing and treating patients. It discusses the revised guidelines for tremor classification and provides recommendations for history-taking and examination. The article also highlights different causes of tremor and management options, emphasizing the importance of accurate diagnosis and individualized treatment.
- Published
- 2023
8. Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge
- Author
-
Evans, Andrew H., Farrell, Michael J., Gibson, Stephen J., Helme, Robert D., and Lim, Shen-Yang
- Published
- 2012
- Full Text
- View/download PDF
9. Clinical Spectrum of Impulse Control Disorders in Parkinsonʼs Disease
- Author
-
Weintraub, Daniel, David, Anthony S., Evans, Andrew H., Grant, Jon E., and Stacy, Mark
- Published
- 2015
- Full Text
- View/download PDF
10. Is Punding a Stereotypy?
- Author
-
Fasano, Alfonso and Evans, Andrew H.
- Published
- 2013
- Full Text
- View/download PDF
11. Postural instability, frontotemporal dementia, and ophthalmoplegia: Clinicopathological case
- Author
-
Cardoso, Francisco, Hodges, John, Evans, Andrew H., Revesz, Tamas, and Williams, David R.
- Published
- 2011
- Full Text
- View/download PDF
12. Parkinsonʼs Disease and Pain—Nondopaminergic Mechanisms are Likely to Be Important Too
- Author
-
Lim, Shen-Yang, Farrell, Michael J., and Evans, Andrew H.
- Published
- 2011
- Full Text
- View/download PDF
13. Sleep disturbance and impulsive-compulsive behaviours in Parkinsonʼs disease
- Author
-
OʼSullivan, Sean S, Loane, Clare M, Lawrence, Andrew D, Evans, Andrew H, Piccini, Paola, and Lees, Andrew J
- Published
- 2011
- Full Text
- View/download PDF
14. Cue-induced striatal dopamine release in Parkinsonʼs disease-associated impulsive-compulsive behaviours
- Author
-
O’Sullivan, Sean S., Wu, Kit, Politis, Marios, Lawrence, Andrew D., Evans, Andrew H., Bose, Subrata K., Djamshidian, Atbin, Lees, Andrew J., and Piccini, Paola
- Published
- 2011
- Full Text
- View/download PDF
15. Progressive Parkinsonism, Oculomotor Abnormalities and Autonomic Dysfunction: Clinicopathological Case
- Author
-
Fabbrini, Giovanni, Merello, Marcello, Evans, Andrew H., Lees, Andrew J., Holton, Janice, and Williams, David R.
- Published
- 2011
- Full Text
- View/download PDF
16. Excessive hoarding in Parkinsonʼs disease
- Author
-
OʼSullivan, Sean S., Djamshidian, Atbin, Evans, Andrew H., Loane, Clare M., Lees, Andrew J., and Lawrence, Andrew D.
- Published
- 2010
- Full Text
- View/download PDF
17. Compulsive use of dopaminergic drug therapy in Parkinsonʼs disease: Reward and anti-reward
- Author
-
Evans, Andrew H., Lawrence, Andrew D., Cresswell, Silke Appel, Katzenschlager, Regina, and Lees, Andrew J.
- Published
- 2010
- Full Text
- View/download PDF
18. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy
- Author
-
Oʼsullivan, Sean S., Djamshidian, Atbin, Ahmed, Zeshan, Evans, Andrew H., Lawrence, Andrew D., Holton, Janice L., Revesz, Tamas, and Lees, Andrew J.
- Published
- 2010
- Full Text
- View/download PDF
19. Reckless generosity in Parkinsonʼs disease
- Author
-
OʼSullivan, Sean S., Evans, Andrew H., Quinn, Niall P., Lawrence, Andrew D., and Lees, Andrew J.
- Published
- 2010
- Full Text
- View/download PDF
20. Impulsive and compulsive behaviors in Parkinsonʼs disease
- Author
-
Evans, Andrew H., Strafella, Antonio P., Weintraub, Daniel, and Stacy, Mark
- Published
- 2009
- Full Text
- View/download PDF
21. Dopamine Dysregulation Syndrome: An Overview of its Epidemiology, Mechanisms and Management
- Author
-
OʼSullivan, Sean S., Evans, Andrew H., and Lees, Andrew J.
- Published
- 2009
- Full Text
- View/download PDF
22. Punding in patients on dopamine agonists for restless leg syndrome
- Author
-
Evans, Andrew H. and Stegeman, James R.
- Published
- 2009
- Full Text
- View/download PDF
23. Impulse Control and Related Disorders in Parkinsonʼs Disease: Review
- Author
-
Lim, Shen-Yang, Evans, Andrew H., and Miyasaki, Janis M.
- Published
- 2008
24. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinsonʼs disease?
- Author
-
Lim, Shen-Yang, Farrell, Michael J., Gibson, Stephen J., Helme, Robert D., Lang, Anthony E., and Evans, Andrew H.
- Published
- 2008
- Full Text
- View/download PDF
25. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis
- Author
-
Evans, Andrew H. and Butzkueven, Helmut
- Published
- 2007
- Full Text
- View/download PDF
26. Punding and Dyskinesias
- Author
-
Silveira-Moriyama, Laura, Evans, Andrew H., Katzenschlager, Regina, and Lees, Andrew J.
- Published
- 2006
- Full Text
- View/download PDF
27. Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence
- Author
-
Serrien, Deborah J., Orth, Michael, Evans, Andrew H., Lees, Andrew J., and Brown, Peter
- Published
- 2005
28. Odor Identification Testing Can Assist in the Clinical Distinction Between Psychiatric Disorders and Neurological/Neurodegenerative Disorders.
- Author
-
Pachi, Ioanna, Evans, Andrew H., Loi, Samantha M., Eratne, Dhamidhu, Malpas, Charles B., Walterfang, Mark, Farrand, Sarah, Kelso, Wendy, Stefanis, Leonidas, and Velakoulis, Dennis
- Abstract
Background/objectives: The aim was to identify whether performance on olfactory identification can distinguish neurological/neurodegenerative disorders (NNDs) from primary psychiatric disorders (PPDs).Methods: This is a cross-sectional retrospective study of inpatients assessed in Neuropsychiatry, Royal Melbourne Hospital. Data extracted from the admission records included: demographics, tobacco use, medical comorbidities, cognitive function using the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), and odor identification using the Sniffin' Sticks Screening 12 test. The final diagnosis for patients was informed by established diagnostic criteria.Results: A total 121 patients were included. Eighty-eight patients (73%) were diagnosed with neurological or neurodegenerative disease, including Alzheimers dementia, frontotemporal dementia, Lewy body parkinsonian-related dementias (Parkinson disease, multiple system atrophy, dementia with Lewy bodies) and other neurological causes of dementia; 33 patients (27%) were diagnosed with PPDs (including mood and psychotic disorders). Patients who scored ≤8 on the Sniffin' Sticks Screening 12 test were more likely to have NND than PPD, even after adjustment for age, sex and tobacco use (P=0.009, adjusted odds ratios=3.85, 95% confidence interval=1.40-10.62). Receiver operating characteristic curve analyses demonstrated that a score of ≤8 differentiated NND from PPD with sensitivity of 57% and specificity of 73% (receiver operating characteristic area under the curve of 0.67, P=0.004).Conclusions: Patients with neuropsychiatric difficulties who score 8 or less on Sniffin' Sticks are more likely to have a neurodegenerative illness. A cut-off score of 8 is potentially a "red flag" for clinicians faced with the diagnostic question of PPD versus NND. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
29. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?
- Author
-
Lawrence, Andrew D, Evans, Andrew H, and Lees, Andrew J
- Published
- 2003
- Full Text
- View/download PDF
30. Protocol for a home-based integrated physical therapy program to reduce falls and improve mobility in people with Parkinson’s disease
- Author
-
Morris Meg E, Martin Clarissa, McGinley Jennifer L, Huxham Frances E, Menz Hylton B, Taylor Nicholas F, Danoudis Mary, Watts Jennifer J, Soh Sze-Ee, Evans Andrew H, Horne Malcolm, and Kempster Peter
- Subjects
Parkinson’s disease ,Accidental falls ,Randomized controlled trial ,Falls prevention ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background The high incidence of falls associated with Parkinson’s disease (PD) increases the risk of injuries and immobility and compromises quality of life. Although falls education and strengthening programs have shown some benefit in healthy older people, the ability of physical therapy interventions in home settings to reduce falls and improve mobility in people with Parkinson’s has not been convincingly demonstrated. Methods/design 180 community living people with PD will be randomly allocated to receive either a home-based integrated rehabilitation program (progressive resistance strength training, movement strategy training and falls education) or a home-based life skills program (control intervention). Both programs comprise one hour of treatment and one hour of structured homework per week over six weeks of home therapy. Blinded assessments occurring before therapy commences, the week after completion of therapy and 12 months following intervention will establish both the immediate and long-term benefits of home-based rehabilitation. The number of falls, number of repeat falls, falls rate and time to first fall will be the primary measures used to quantify outcome. The economic costs associated with injurious falls, and the costs of running the integrated rehabilitation program from a health system perspective will be established. The effects of intervention on motor and global disability and on quality of life will also be examined. Discussion This study will provide new evidence on the outcomes and cost effectiveness of home-based movement rehabilitation programs for people living with PD. Trial registration The trial is registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12608000390381).
- Published
- 2012
- Full Text
- View/download PDF
31. Punding in Parkinson's disease
- Author
-
O'Sullivan, Sean S., Evans, Andrew H., and Lees, Andrew J.
- Subjects
Compulsive behavior -- Causes of ,Stereotype (Psychology) -- Psychological aspects ,Parkinson's disease -- Psychological aspects ,Parkinson's disease -- Case studies ,Parkinson's disease -- Care and treatment ,Health ,Psychology and mental health - Published
- 2007
32. Parkinsonism as a Third Wave of the COVID-19 Pandemic?
- Author
-
Beauchamp, Leah C., Finkelstein, David I., Bush, Ashley I., Evans, Andrew H., and Barnham, Kevin J.
- Subjects
COVID-19 pandemic ,PARKINSONIAN disorders ,SARS-CoV-2 ,PARKINSON'S disease ,COVID-19 ,ANTI-NMDA receptor encephalitis - Abstract
Since the initial reports of COVID-19 in December 2019, the world has been gripped by the disastrous acute respiratory disease caused by the SARS-CoV-2 virus. There are an ever-increasing number of reports of neurological symptoms in patients, from severe (encephalitis), to mild (hyposmia), suggesting the potential for neurotropism of SARS-CoV-2. This Perspective investigates the hypothesis that the reliance on self-reporting of hyposmia has resulted in an underestimation of neurological symptoms in COVID-19 patients. While the acute effect of the virus on the nervous system function is vastly overshadowed by the respiratory effects, we propose that it will be important to monitor convalescent individuals for potential long-term implications that may include neurodegenerative sequelae such as viral-associated parkinsonism. As it is possible to identify premorbid harbingers of Parkinson's disease, we propose long-term screening of SARS-CoV-2 cases post-recovery for these expressions of neurodegenerative disease. An accurate understanding of the incidence of neurological complications in COVID-19 requires long-term monitoring for sequelae after remission and a strategized health policy to ensure healthcare systems all over the world are prepared for a third wave of the virus in the form of parkinsonism. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries.
- Author
-
Bhidayasiri, Roongroj, Phokaewvarangkul, Onanong, Sakdisornchai, Karn, Boonpang, Kamolwan, Chaudhuri, K. Ray, Parsons, Jan, Lolekha, Praween, Chairangsaris, Parnsiri, Srivanitchapoom, Prachaya, Benedierks, Sharon, Panyakaew, Pattamon, Boonmongkol, Thanatat, Thongchuam, Yuwadee, Kantachadvanich, Nitinan, Phumphid, Saisamorn, Evans, Andrew H., Viriyavejakul, Akravudh, Pisarnpong, Apichart, van Laar, Teus, and Jagota, Priya
- Abstract
The increasing global burden of Parkinson's disease (PD) poses a particular challenge for developing countries, such as Thailand, when delivering care to a geographically diverse populace with limited resources, often compounded by a lack of expertise in the use of certain PD medications, such as device-aided therapies (DAT). A panel of local, regional, and international PD experts convened to review the unmet needs of PD in Thailand and share insights into effective delivery of DAT, focusing on experience with apomorphine infusion. Despite its proven efficacy and safety, implementation of apomorphine infusion as a new option was not straightforward. This has prompted a range of health-care professional and patient-focused initiatives, led by the Chulalongkorn Center of Excellence for Parkinson's Disease and Related Disorders in Bangkok, to help establish a more coordinated approach to PD management throughout the country and ensure patients have access to suitable treatments. Overcoming the challenges of education, proficiency, resource capacity and standard of care for PD patients in developing countries requires a coordinated effort both nationally and beyond. The best practices identified in Thailand following the introduction of apomorphine infusion might be helpful for other countries when implementing similar programs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience.
- Author
-
Fasano, Alfonso, Antonini, Angelo, Katzenschlager, Regina, Krack, Paul, Odin, Per, Evans, Andrew H., Foltynie, Thomas, Volkmann, Jens, and Merello, Marcelo
- Subjects
PARKINSON'S disease ,COVID-19 ,NEUROLOGISTS ,DEEP brain stimulation ,INFUSION therapy ,MEDICAL care - Abstract
Background: Although the COVID‐19 pandemic is affecting a relatively small proportion of the global population, its effects have already reached everyone. The pandemic has the potential to differentially disadvantage chronically ill patients, including those with Parkinson's disease (PD). The first health care reaction has been to limit access to clinics and neurology wards to preserve fragile patients with PD from being infected. In some regions, the shortage of medical staff has also forced movement disorders neurologists to provide care for patients with COVID‐19. Objective: To share the experience of various movement disorder neurologists operating in different world regions and provide a common approach to patients with PD, with a focus on those already on advanced therapies, which may serve as guidance in the current pandemic and for emergency situations that we may face in the future. Conclusion: Most of us were unprepared to deal with this condition given that in many health care systems, telemedicine has been only marginally available or only limited to email or telephone contacts. In addition, to ensure sufficient access to intensive care unit beds, most elective procedures (including deep brain stimulation or the initiation of infusion therapies) have been postponed. We all hope there will soon be a time when we will return to more regular hospital schedules. However, we should consider this crisis as an opportunity to change our approach and encourage our hospitals and health care systems to facilitate the remote management of chronic neurological patients, including those with advanced PD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
35. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.
- Author
-
Evans, Andrew H., Okai, David, Weintraub, Daniel, Lim, Shen‐Yang, O'Sullivan, Sean S., Voon, Valerie, Krack, Paul, Sampaio, Cristina, Post, Bart, Leentjens, Albert F.G., Martinez‐Martin, Pablo, Stebbins, Glenn T., Goetz, Christopher G., Schrag, Anette, Bhidayasiri, Roongroj, Brown, Richard G., Marinus, Johan, Mestre, Tiago A., Violante, Mayela Rodriguez, and Skorvanek, Matej
- Subjects
- *
BEHAVIOR , *COMPULSIVE behavior , *PARKINSON'S disease , *PSYCHOLOGICAL tests , *SYSTEMATIC reviews , *DISEASE complications - Abstract
Impulse control disorders (ICDs) and related impulsive and compulsive behaviors (together called ICBs) have been increasingly recognized in the context of Parkinson's disease (PD) and treatment. The International Parkinson's and Movement Disorder Society commissioned a task force to assess available clinical screening instruments and rating scales, including their clinimetric properties, make recommendations regarding their utility, and suggest future directions in scale development and validation. The literature was systematically searched for scales measuring a range of reported ICBs in PD. A scale was designated "recommended" if the scale had been employed in PD studies, been used beyond the group that developed it, and had adequate clinimetric data published for PD. Numerous diagnostic screening tools and severity rating scales were identified for a range of ICBs, including compulsive medication use, punding/hobbyism, walkabout, pathological gambling, hypersexuality, compulsive or binge eating, compulsive buying, reckless driving, compulsive exercise, pyromania, trichotillomania, hoarding, kleptomania, intermittent explosive disorder, and internet addiction. For screening across the range of ICBs (except compulsive medication use), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) and QUIP-Rating Scale (QUIP-RS) are recommended, and for severity rating across the range of ICBs the QUIP-RS and the Ardouin Scale of Behavior in Parkinson's Disease are recommended. The Scale for Outcomes in Parkinson's Disease-Psychiatric Complications is recommended for rating of hypersexuality and the compulsive behaviors gambling/shopping. Further testing of established scales against gold standard diagnostic criteria is urgently required for all other individual ICBs in PD. © 2019 International Parkinson and Movement Disorder Society © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Deep brain stimulation for severe treatment-resistant obsessive-compulsive disorder: An open-label case series.
- Author
-
Farrand, Sarah, Evans, Andrew H., Mangelsdorf, Simone, Loi, Samantha M., Mocellin, Ramon, Borham, Adam, Bevilacqua, JoAnne, Blair-West, Scott, Walterfang, Mark A., Bittar, Richard G., and Velakoulis, Dennis
- Subjects
- *
TELENCEPHALON , *OBSESSIVE-compulsive disorder , *ANXIETY , *MENTAL depression , *PSYCHOSURGERY , *SOCIAL participation , *TREATMENT effectiveness , *SEVERITY of illness index , *DISEASE duration , *DEEP brain stimulation , *PHYSIOLOGY , *THERAPEUTICS - Abstract
Objective: Deep brain stimulation can be of benefit in carefully selected patients with severe intractable obsessive-compulsive disorder. The aim of this paper is to describe the outcomes of the first seven deep brain stimulation procedures for obsessive-compulsive disorder undertaken at the Neuropsychiatry Unit, Royal Melbourne Hospital. The primary objective was to assess the response to deep brain stimulation treatment utilising the Yale-Brown Obsessive Compulsive Scale as a measure of symptom severity. Secondary objectives include assessment of depression and anxiety, as well as socio-occupational functioning. Methods: Patients with severe obsessive-compulsive disorder were referred by their treating psychiatrist for assessment of their suitability for deep brain stimulation. Following successful application to the Psychosurgery Review Board, patients proceeded to have deep brain stimulation electrodes implanted in either bilateral nucleus accumbens or bed nucleus of stria terminalis. Clinical assessment and symptom rating scales were undertaken pre- and post-operatively at 6- to 8-week intervals. Rating scales used included the Yale-Brown Obsessive Compulsive Scale, Obsessive Compulsive Inventory, Depression Anxiety Stress Scale and Social and Occupational Functioning Assessment Scale. Results: Seven patients referred from four states across Australia underwent deep brain stimulation surgery and were followed for a mean of 31 months (range, 8–54 months). The sample included four females and three males, with a mean age of 46 years (range, 37–59 years) and mean duration of obsessive-compulsive disorder of 25 years (range, 15–38 years) at the time of surgery. The time from first assessment to surgery was on average 18 months. All patients showed improvement on symptom severity rating scales. Three patients showed a full response, defined as greater than 35% improvement in Yale-Brown Obsessive Compulsive Scale score, with the remaining showing responses between 7% and 20%. Conclusion: Deep brain stimulation was an effective treatment for obsessive-compulsive disorder in these highly selected patients. The extent of the response to deep brain stimulation varied between patients, as well as during the course of treatment for each patient. The results of this series are comparable with the literature, as well as having similar efficacy to ablative psychosurgery techniques such as capsulotomy and cingulotomy. Deep brain stimulation provides advantages over lesional psychosurgery but is more expensive and requires significant multidisciplinary input at all stages, pre- and post-operatively, ideally within a specialised tertiary clinical and/or academic centre. Ongoing research is required to better understand the neurobiological basis for obsessive-compulsive disorder and how this can be manipulated with deep brain stimulation to further improve the efficacy of this emerging treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor.
- Author
-
Boonstra, Frederique M. C., Perera, Thushara, Noffs, Gustavo, Marotta, Cassandra, Vogel, Adam P., Evans, Andrew H., Butzkueven, Helmut, Moffat, Bradford A., van der Walt, Anneke, and Kolbe, Scott C.
- Subjects
FUNCTIONAL magnetic resonance imaging ,TREMOR ,PATHOLOGICAL physiology - Abstract
Introduction: Tremor of the upper limbs is a disabling symptom that is present during several neurological disorders and is currently without treatment. Functional MRI (fMRI) is an essential tool to investigate the pathophysiology of tremor and aid the development of treatment options. However, no adequately or standardized protocols for fMRI exists at present. Here we present a novel, online available fMRI task that could be used to assess thein vivo pathology of tremor.Objective: This study aims to validate the tremor-evoking potential of the fMRI task in a small group of tremor patients outside the scanner and assess the reproducibility of the fMRI task related activation in healthy controls.Methods: Twelve HCs were scanned at two time points (baseline and after 6-weeks). There were two runs of multi-band fMRI and the tasks included a “brick-breaker” joystick game. The game consisted of three conditions designed to control for most of the activation related to performing the task by contrasting the conditions: WATCH (look at the game without moving joystick), MOVE (rhythmic left/right movement of joystick without game), and PLAY (playing the game). Task fMRI was analyzed using FSL FEAT to determine clusters of activation during the different conditions. Maximum activation within the clusters was used to assess the ability to control for task related activation and reproducibility. Four tremor patients have been included to test ecological and construct validity of the joystick task by assessing tremor frequencies captured by the joystick.Results: In HCs the game activated areas corresponding to motor, attention and visual areas. Most areas of activation by our game showed moderate to good reproducibility (intraclass correlation coefficient (ICC) 0.531–0.906) with only inferior parietal lobe activation showing poor reproducibility (ICC 0.446). Furthermore, the joystick captured significantly more tremulous movement in tremor patients compared to HCs (p = 0.01) during PLAY, but not during MOVE.Conclusion: Validation of our novel task confirmed tremor-evoking potential and reproducibility analyses yielded acceptable results to continue further investigations into the pathophysiology of tremor. The use of this technique in studies with tremor patient will no doubt provide significant insights into the treatment options. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
38. Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease.
- Author
-
Lee, Will, Evans, Andrew H., and Williams, David R.
- Subjects
- *
HEALTH , *SLEEP , *PARKINSON'S disease patients , *MOTOR ability , *DISEASE prevalence , *MOVEMENT disorder treatments - Abstract
Background Sleep benefit ( SB) in Parkinson's disease refers to improved motor symptoms upon waking despite an entire night without medications. Although it was first proposed 30 years ago, this phenomenon proved difficult to investigate, and its true prevalence and underlying mechanisms remain unclear. Objective This study aimed to identify and quantify SB through measurement of motor function using a validated smartphone application and to identify disease characteristics that predicted SB. Methods Ninety-two patients recruited from 2 Movement Disorder Services were clinically assessed at home using a validated smartphone application. Each patient was tested in the on-state, at the end of dose, and on waking (before medications) 3 times. Differences between the 3 states were used to determine the impact of sleep and levodopa on motor function. SB was considered to be a 'measurable improvement in parkinsonism from the end of dose.' Results The morning waking motor function of 20 patients (22%) improved compared with the end-of-dose function, with 9 patients demonstrating superior function compared with their on-state. No clinical features predicted SB. Although all participants subjectively reported motor fluctuations, only 35 patients (38%) demonstrated an objective improvement with levodopa. Patients who had SB more often demonstrated objective motor fluctuations compared with those who did not (65% vs. 31%; P = 0.008). Conclusions SB is a genuine motor phenomenon: 1 in 5 patients have a measurable improvement in motor function on waking. It remains questionable whether this improvement is a direct effect of sleep. Until its underlying mechanism is better understood, it is more appropriate to refer to this phenomenon as simply morning improvement or diurnal fluctuation of motor symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. A guide to management of neuropsychiatric manifestations of Parkinson's disease.
- Author
-
Molina Ruiz, Rosa M., Evans, Andrew H., Velakoulis, Dennis, Looi, Jeffrey C. L., and Looi, Jeffrey Cl
- Subjects
- *
PARKINSON'S disease treatment , *NEUROBEHAVIORAL disorders , *PSYCHIATRIC drugs , *DISEASE complications , *MEDICAL protocols , *DISEASE risk factors , *DOPA , *CLASSIFICATION of mental disorders , *MENTAL illness treatment , *DRUG therapy for Parkinson's disease , *PARKINSON'S disease , *SYSTEMATIC reviews , *PSYCHOLOGY , *THERAPEUTICS - Abstract
Objective: This clinical update review focuses on treatment approaches of neuropsychiatric manifestations in Parkinson's disease.Methods: We conducted a systematic search of the literature using Pubmed and selected recent and relevant papers for this review.Results: Neuropsychiatric symptoms in Parkinson's disease usually require optimization of levodopa therapy as a first step. Most psychotropic drugs can be used in Parkinson's disease, however there is still lack of an evidence base due to limited studies and difficulties in diagnosis of neuropsychiatric disorders. Non-pharmacological treatments have also proved effective in Parkinson's disease. Cognitive impairment requires special consideration.Conclusions: Management of neuropsychiatric manifestations in Parkinson's disease is complicated by the lack of evidence. Treatment should be individualized and benefits and risks must be balanced. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
40. Neuropsychiatric manifestations of Parkinson's disease.
- Author
-
Molina Ruiz, Rosa M., Evans, Andrew H., Velakoulis, Dennis, Looi, Jeffrey C. L., and Looi, Jeffrey Cl
- Subjects
- *
DISEASE risk factors , *PARKINSON'S disease , *PARKINSON'S disease treatment , *PARKINSON'S disease diagnosis , *NEUROBEHAVIORAL disorders , *NEUROPSYCHOLOGICAL tests , *PATHOLOGICAL psychology , *META-analysis , *CLASSIFICATION of mental disorders , *PSYCHIATRIC epidemiology , *PSYCHIATRY , *SYSTEMATIC reviews , *PSYCHOLOGY - Abstract
Objective: This clinical update review focuses on the classification and description of common neuropsychiatric manifestations in Parkinson's disease (PD).Method: We conducted a systematic search of the literature using Pubmed and selected the most recent and relevant papers for this review.Results: Neuropsychiatric manifestations in PD are are very frequent and may arise from an abnormal psychopathological response to the disease, neurobiological changes related to the disease itself, complications of treatments or a combination of all of these.Conclusions: Neuropsychiatric symptoms may precede the motor clinical presentation of PD. Early recognition is essential. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor.
- Author
-
Evans, Andrew H. and Chai, Chiun-Hian
- Abstract
Background. Nonmotor symptoms particularly olfactory dysfunction, RBD, depression, hallucinations, and constipation are currently not included in the typical clinical criteria for diagnosing Lewy body Parkinsonian disorders (LBPD). The aim of this study is to determine the diagnostic value of nonmotor symptoms in patients presenting with Parkinsonism and tremor. Methods. All new patients seen between January 2007 and May 2013 in the Movement Disorders Specialist Clinics of the Royal Melbourne Hospital (RMH), who were referred with a possible neurodegenerative syndrome or concerns of Parkinsonism and/or tremor, were included. Patients underwent routine evaluation with the four-minute “Sniffin Sticks” test, RBD, depression, and constipation. Results. 291 patients were included in the analysis. Conclusion. We found that lower olfaction scores based on “Sniffin Sticks” testing combined with reports of depression and constipation are independent predictors for the diagnosis of the spectrum of Lewy body Parkinsonian disorders (LBPD). Parkinson’s disease (PD) cannot be reliably clinically differentiated from other causes of Parkinsonism that share symptomatology and structural abnormalities. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. The relationship between specific cognitive defects and burden of care in Parkinson's disease.
- Author
-
Zhong, Michael, Peppard, Richard, Velakoulis, Dennis, and Evans, Andrew H.
- Abstract
Background: In spite of the recognized physical and psychosocial effects of caring for patients with Parkinson's disease (PD), caregiver burden (CB) in this setting is poorly understood. The objective of this research was to identify factors that were associated with CB in an Australian population of PD caregivers using a novel instrument - the Parkinson's Disease Caregiver Burden (PDCB) questionnaire.Methods: Fifty patient-caregiver couples were recruited from three movement disorders clinics in Melbourne, Australia. Burden on caregivers was rated using the PDCB questionnaire. Burden scores were correlated with patient factors, including motor symptom severity (Unified Parkinson's Disease Ratings Scale and Hoehn & Yahr (H&Y) scale), patient cognition (Neuropsychiatry Unit Cognitive Assessment Tool; NUCOG), presence of impulsive and compulsive behaviors (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease), and patient olfaction. Caregiver and patient demographics, as well as results for depression and anxiety (Hospital Anxiety and Depression Scale; HADS), were also examined for their relationship with CB.Results: H&Y stage, depression or anxiety in either caregiver or patient, and decreased patient NUCOG score were significantly associated with higher PDCB score. Multiple linear regression analysis identified caregiver and patient depression score and patient score for the visuoconstructional subscale of NUCOG to predict burden score. In addition, disease duration, duration of caregiving, and increased hours per day spent in giving care were significantly associated with increased burden.Conclusions: We found psychiatric and cognitive factors to be the most relevant factors in the perception of burden in PD caregivers. On top of this, we found deficits in the domain of visuoconstruction predicted burden - a relationship not yet described in literature. Targeting depression and anxiety in this setting as well as identifying caregivers at high risk of burden may give clinicians the chance to optimize care of patients with PD through the caregiver. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
43. The diagnostic challenge among young onset dementia syndromes and primary psychiatric diseases: Results of a retrospective, 20‐year cross‐sectional study.
- Author
-
Tsoukra, Paraskevi, Velakoulis, Dennis, Wibawa, Pierre, Malpas, Charles B, Walterfang, Mark, Evans, Andrew H, Farrand, Sarah, Kelso, Wendy, Eratne, Dhamidhu, and Loi, Samantha M
- Abstract
Background: Distinguishing a dementia syndrome from a primary psychiatric disease in younger patients can be challenging and may lead to diagnostic change over time. The aim of this study was to examine diagnostic stability in a cohort of patients with younger‐onset neurocognitive disorders. Method: We retrospectively reviewed records of patients that were admitted to our unit between 2000 and 2019, were followed‐up for ≥12 months and received a diagnosis of young onset dementia at any time point. Initial diagnosis included Alzheimer disease (AD)‐type dementia (n= 30), frontotemporal dementia (FTD) syndromes (n=44), vascular dementia (VaD, n=7), mild cognitive impairment (MCI, n= 10), primary psychiatric diseases (n=6) and other conditions such as Lewy Body Dementia (n=30). Result: In a total of n=127 patients, 49 (39%) changed their initial diagnoses during follow‐up. Behavioural variant FTD (bvFTD) was the least stable diagnosis, followed by dementia not otherwise specified and MCI. Compared to patients with a stable diagnosis, those who changed exhibited: a higher cognitive score at baseline, a longer follow‐up period, greater delay to final diagnosis, and no family history of dementia. Patients switching from a neurodegenerative to a psychiatric diagnosis more likely had a long psychiatric history, while those changing from a psychiatric to a neurodegenerative diagnosis had a recent manifestation of psychiatric symptoms. Conclusion: Misdiagnosis in younger patients with neurocognitive disorders is not uncommon, especially in cases of behavioural variant FTD. Late‐onset psychiatric symptoms may be the harbinger to a neurodegenerative disease. Close follow‐up and monitoring of these patients are necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. A Conditioned Response as a Measure of Impulsive-Compulsive Behaviours in Parkinson's Disease.
- Author
-
Evans, Andrew H., Kettlewell, Jade, McGregor, Sarah, Kotschet, Katya, Griffiths, Robert I., and Horne, Malcolm
- Subjects
- *
CONDITIONED response , *COMPULSIVE behavior , *PARKINSON'S disease , *HYPOKINESIA , *DYSKINESIAS , *MENTAL depression , *NEUROSCIENCES - Abstract
Objectives: Parkinson's Disease patients wore a device on the wrist that gave reminders to take levodopa and also measured bradykinesia and dyskinesia. Consumption of medications was acknowledged by placing the thumb on the device. Some patients performed this acknowledgement repeatedly and unconsciously. This study examines whether this behaviour reflected increased impulsivity. Methods and Results: Twenty five participants were selected because they had i) excess acknowledgements described above or ii) Impulsive-Compulsive Behaviours or iii) neither of these. A blinded assessor applied clinical scales to measure Impulsive-Compulsive Behaviours, cognition, depression, anxiety and apathy. A Response Ratio, representing the number of acknowledgements/number of doses (expressed as a percentage) was tightly correlated with ratings of Impulsive-Compulsive Behaviours (r2 = 0.79) in 19/25 subjects. Some of these patients had dyskinesia, which was higher with extraneous responses than with response indicating medication consumption. Six of the 25 subjects had high Impulsive-Compulsive Behaviour Scores, higher apathy scores, low levels of dyskinesia and normal Response Ratios. Patients without ICB (low RR) also had low dyskinesia levels regardless of the relevance of the response. Conclusion: An elevated Response Ratio is a specific measure of a type of ICB where increased incentive salience is attributed to cues by the presence of high striatal dopamine levels, manifested by high levels of dyskinesia. This study also points to a second form of ICBs which occur in the absence of dyskinesia, has normal Response Ratios and higher apathy scores, and may represent prefrontal pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
45. BeYOND: Biomarkers in younger‐onset neurocognitive disorders — The first 50 participants: Neuropsychiatry and behavioral neurology/Neuropsychiatry.
- Author
-
Loi, Samantha M., Eratne, Dhamidhu, Waterfang, Mark, Kelso, Wendy, Farrand, Sarah, Goh, Anita M.Y., Chadunow, Carolyn, Ravenfar, Parsa Seyed, Watson, Rosie, Evans, Andrew H., Vidaurre, Lesley, and Velakoulis, Dennis
- Abstract
Background: There are currently 28000 people in Australia with younger‐onset dementia (YOD). A recent review of younger‐onset dementia cohorts (Loi SM et al. submitted) suggested that there needs to be more detailed study in this heterogenous group in order to glean more clinically relevant information. For example, our group (Eratne D et al. 2020) investigated the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) chain in a group of people with a range of psychiatric and neurodegenerative disorders and reported that NfL could distinguish between these two broad disorders, demonstrating the benefits in studying a large range of YODs. BeYOND (Biomarkers in younger‐onset neurocognitive disorders) was established as a longitudinal cohort of younger people presenting with neurocognitive symptoms to a clinical diagnostic service, with the aim of identifying clinical and investigational biomarkers which can inform diagnostic and psychosocial outcomes in a clinically heterogenous population. Method: Patients are prospectively recruited during their index presentation to Neuropsychiatry, Royal Melbourne Hospital, Australia. Neuropsychiatry is a tertiary specialist service which provides diagnostic work‐up for patients with cognitive, psychiatric and neurological symptoms. The diagnostic process includes baseline and 18 month assessments of clinical and diagnostic outcomes including CSF and blood biomarkers, cognition, neuroimaging and psychosocial (including caregiver). Results: To date, 50 participants have been recruited (17 females, mean age 55). Thirty of had a dementia diagnosis (including Alzheimer's dementia, frontotemporal dementia and Huntington's disease), with the remainder having a psychiatric disorder (including depression and schizophrenia) as principle diagnosis. All participants have had clinical, neuropsychology and imaging. Eleven have had a lumbar puncture. Twenty participants have had a research blood panel for genetic analysis)and 12 had quantitative susceptibility mapping imaging. Conclusion: The diagnosis of neurodegenerative disorders in younger people can be difficult and is often associated with diagnostic delays (Draper B et al. 2016). The BeYOND study aims to longitudinally assess younger patients with suspected neurodegenerative disease in order to improve diagnostic and psychosocial outcomes for this population. References: Loi SM et al. J Neuropsychiatry Clin Neuroscience. Submitted 23/1/2020. Eratne D et al. ANZJP. 54 (1): 57‐67. 2020. Draper B et al. Int J Geriatr Psychiatry. 31 (11): 1217‐1224. 2016. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Sniffin' Sticks Screening 12 Test can assist in the clinical distinction between psychiatric disorders and neurological/neurodegenerative disorders: Biomarkers (non‐neuroimaging) / Differential diagnosis.
- Author
-
Pachi, Ioanna, Evans, Andrew H, Loi, Samantha M, Eratne, Dhamidhu, Malpas, Charles B, Walterfang, Mark, Farrand, Sarah, Kelso, Wendy, and Velakoulis, Dennis
- Abstract
Background: Distinguishing primary psychiatric disorders (PPD) from neurological/neurodegenerative disorders (NND) is a common diagnostic dilemma in clinical practice. Numerous studies have focused on whether cognitive, neuroimaging or blood/ cerebrospinal fluid (CSF) are of assistance in this clinical scenario. Olfactory impairment has not however been systematically examined as a clinical tool for this purpose. The aim of this study was to identify whether performance in olfactory identification can distinguish NND and PPD. Method: This was a cross‐sectional retrospective study of inpatients assessed in Neuropsychiatry, Royal Melbourne Hospital (RMH) over the period 2015‐2019. Neuropsychiatry is a tertiary / quaternary service which provides diagnostic work up for patients with cognitive, psychiatric and neurological symptoms. Data extracted from the admission records included: demographics, tobacco use, medical comorbidities, cognitive function using the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), and odour identification assessed using the Sniffin' Sticks Screening 12 Test (SS12). The final discharge diagnosis for all patients was informed by established diagnostic criteria. Result: 121 patients were identified who had valid Sniffin Stick testing over this period. 88 patients (72.7%) were diagnosed with NND (mean age‐ 60, including Alzheimer's dementia, frontotemporal dementia, Lewy body parkinsonian‐related dementias [Parkinson's disease, Multiple Systematic Atrophy, Dementia with Lewy bodies] and other neurological causes of dementia), 33 patients (27.3%) were diagnosed with PPD (mean age=57 years, including mood and psychotic disorders). Patients who scored ≤8 in SS12 were more likely to have NND than PPD, even after adjustment for age, gender and tobacco use [(p=0.005, unadjusted OR=3.51, 95% CI=1.463,8.410), (p=0.009, adjusted OR=3.848, 95% CI=1.395,10.617)]. Receiver Operating Curve (ROC) analyses demonstrated that a score of ≤8 differentiated NND from PSY with sensitivity of 56.8% and specificity of 72.7% (ROC area under the curve of 0.672, p=0.004). Conclusion: Patients presenting with diagnostically complex neurocognitive / neuropsychiatric difficulties who score 8 or less on Sniffin' Sticks are more likely to have a neurodegenerative illness. A cut‐off score of 8 is potentially a "red‐flag" for clinicians faced with the diagnostic question of PPD versus NND. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Neurofilament light chain in psychiatric and neurodegenerative disorders: A 'c‐reactive protein' for the brain?: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers.
- Author
-
Eratne, Dhamidhu, Loi, Samantha M., Santillo, Alexander, Li, Qiao‐Xin, Chadunow, Carolyn, Stehmann, Christiane, Janelidze, Shorena, Malpas, Charles B., Walia, Nirbaanjot, Varghese, Shiji, Dhiman, Kunal, Lewis, Vicki, Senesi, Mateo, Evans, Andrew H., Kelso, Wendy, Farrand, Sarah, McGlade, Amelia, Goh, Anita M. Y., Fowler, Christopher J., and Vivash, Lucy E.
- Abstract
Background: Accurate diagnosis of a neurodegenerative disorder, in particular distinguishing primary psychiatric from neurological disorders, can be challenging. There is a need for biomarkers to reduce the diagnostic odyssey and improve outcomes. Neurofilament light (NfL) has shown promise as a biomarker for diagnosis, staging and prognosis in a wide range of disorders. Our 'Biomarkers in Younger Onset Neurocognitive Disorders' (BeYOND) and 'Markers in Neuropsychiatric Disorders' (MiND) studies aim to build on our pilot study (Eratne et al, 2019, ANZJP), to explore the diagnostic and broader utility of plasma and cerebrospinal fluid (CSF) NfL, in a broad range of psychiatric and neurodegenerative/neurological disorders. Method: These studies assess plasma and/or CSF NfL concentrations using Simoa technology in a broad range of cohorts, including: patients assessed for neurocognitive/psychiatric symptoms at Neuropsychiatry and Melbourne Young Onset Dementia service; Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR); treatment trials in Alzheimer's disease (AD) and frontotemporal dementia (FTD); treatment‐resistant schizophrenia (TRS) biobank; FTD; autoimmune encephalitis; Niemann‐Pick Type C; epilepsy; and patients in primary care with cognitive or psychiatric symptoms. The most recent primary consensus diagnosis informed by established diagnostic criteria is categorised: psychiatric disorder (PSY), neurodegenerative/neurological disorder (NND), or healthy controls (HC). Result: As of January 2020, data from 485 patients/participants (NND:325, PSY:100, HC:60) demonstrates significantly elevated plasma and/or CSF NfL levels in a broad range of NND compared to a broad range of PSY, and HC, with areas under the curve of>0.90 and sensitivity and specificity>90%: improving on results from our pilot study. As recruitment, sample analysis, data collection is ongoing, more detailed, up to date results will be presented from over 600 patients/participants, including in‐depth findings from TRS, ANCJDR, AD and FTD treatment trials, and general practice cohorts. Conclusion: NfL shows great promise as a diagnostic test to assist with the common, but challenging diagnostic dilemma of distinguishing psychiatric from neurodegenerative and neurological disorders. A significantly elevated NfL concentration in a patient with a psychiatric diagnosis should prompt consideration of neurological or neurodegenerative differentials. Plasma NfL could dramatically alter clinical care of patients with neurological/neurodegenerative and psychiatric disorders, improving outcomes for patients, their families, the healthcare system, and clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Excessive hoarding in Parkinson's disease.
- Author
-
O'Sullivan, Sean S., Djamshidian, Atbin, Evans, Andrew H., Loane, Clare M., Lees, Andrew J., and Lawrence, Andrew D.
- Abstract
Hoarding is seen in several psychiatric conditions, but has not been specifically assessed in Parkinson's disease (PD). This study investigates hoarding tendency amongst patients with PD, and its association with impulsive-compulsive spectrum behaviors (ICBs). We compare clinical features, measures of hoarding, impulse buying, self-control, obsessive-compulsive symptoms, depression, and anxiety in 39 patients with PD with ICBs (PD + ICB), 61 patients with PD without ICBs (PD − ICB), and 50 healthy controls. A much higher proportion of PD + ICB (27.8%) than PD − ICB (3.5%) were hoarders ( P = 0.001). 6% of healthy controls were hoarders. Compulsive shoppers scored higher than other varieties of ICB on excessive acquisition measures. Hoarding correlated positively with impulsive buying, obsessive-compulsive symptoms, PD duration, and negatively with self-control measures. Using multivariate regression analyzes, the presence of ICBs and measures of impulsive buying were the only variables independently associated with hoarding in PD. The association of hoarding with other ICBs and low trait impulse control suggests that excessive hoarding is related to the spectrum of impulsive behaviors in PD. © 2010 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
49. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy.
- Author
-
O'Sullivan, Sean S., Djamshidian, Atbin, Ahmed, Zeshan, Evans, Andrew H., Lawrence, Andrew D., Holton, Janice L., Revesz, Tamas, and Lees, Andrew J.
- Abstract
There is growing awareness of impulsive-compulsive spectrum behaviors (ICBs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT). These include pathological gambling, hypersexuality, compulsive shopping, binge eating, punding and compulsive use of DRT, or dopamine dysregulation syndrome. In PD, difficulties exist in separating the effects of DRT from the underlying disease process and aberrant dopaminergic systems in determining the aetiology of ICBs. Recent reports of ICBs associated with dopamine agonist use for conditions other than PD may suggest a significant etiological role for these medications, but currently published cases thus far lack pathological confirmation of diagnoses. We present three cases of pathologically confirmed progressive supranuclear palsy who developed ICBs in association with dopamine agonist use. Pathological comparisons between these three cases and other case series of progressive supranuclear palsy are made. © 2010 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
50. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease.
- Author
-
Lim, Shen-Yang, O’Sullivan, Sean S., Kotschet, Katya, Gallagher, David A., Lacey, Cameron, Lawrence, Andrew D., Lees, Andrew J., O’Sullivan, Dudley J., Peppard, Richard F., Rodrigues, Julian P., Schrag, Anette, Silberstein, Paul, Tisch, Stephen, and Evans, Andrew H.
- Subjects
PARKINSON'S disease treatment ,BRAIN stimulation ,IMPULSE control disorders ,DOPAMINE ,SYMPTOMS ,CASE studies ,COMPULSIVE gambling ,HEALTH outcome assessment - Abstract
Abstract: Data regarding the effect of deep brain stimulation (DBS) surgery on the dopamine dysregulation syndrome (DDS), impulse control disorders (ICDs) and punding in Parkinson’s disease (PD) are limited. We present a case series of 21 operated PD patients who had exhibited DDS, ICDs or punding at some stage during the disease. DDS remained unimproved or worsened post-operatively in 12/17 patients with pre-operative DDS (71%) (nine bilateral subthalamic nucleus [STN], one right-sided STN, two bilateral globus pallidus internus [GPi] DBS). DDS improved or resolved after bilateral STN DBS in 5/17 patients with pre-operative DDS. DDS apparently developed for the first time after bilateral STN DBS in two patients, although only after a latency of eight years in one case. One patient without reported pre-operative DDS or ICDs developed pathological gambling post-STN DBS. One patient had pathological gambling which resolved pre-operatively, and did not recur post-DBS. Thus, DDS, ICDs and punding may persist, worsen or develop for the first time after DBS surgery, although a minority of patients improved dramatically. Predictive factors may include physician vigilance, motor outcome and patient compliance. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.